New Curcumin Extract Found to Counteract Inflammation At the Transcriptional Level
Vancouver, CANADA, October 5, 2016 – New biomedical research discovery released today shows that a trace component of the standard curcumin extract, bisdemethoxycurcumin (BDMC), is shown by Biologic Pharmamedical Research to inhibit inflammation in a different way from how regular curcumin extract inhibits inflammation. This discovery allows curcumin pharmacology to be more precisely targeted for therapeutic results.
The research on this patented discovery is the work of The Rhema Group’s Chief Science Officer, Franco Cavaleri, B.Sc., Ph.D. candidate. He is the principal research scientist at Biologic Pharmamedical. Cavaleri’s research shows for the first time how the modified curcumin extract (BDM30) targets and neutralizes TWO key proteins (NF-kB and MSK1) central in the regulation of inflammation while the typical curcumin extract 95% inhibits one protein (NF-kB).
“Inflammation is central to every disease pathology at one level or another. This new pointed pharmacological research on curcumin reveals that although BDMC exists in extremely low concentrations in standardized curcumin extracts – between 0.5% to 1.5% – it can play a key role in therapy if it is raised to 30%. This composition enhancement fortifies the mechanism by which curcumin can inhibit nuclear, MSK1, a facilitative kinase protein central to the inflammatory process. MSK1, is more recently shown to be dysregulated in diseases like drug resistant cancers and chronic or drug resistant autoimmune disease.” says Cavaleri. ” Nevertheless, much work remains to be done to be able to determine how this activity can be applied to treat specific disease conditions.”
This new understanding reveals how curcumin pharmacology can be designed to be more selective in targeting specific genomic activity. Elevated levels of BDMC to 30% is showing dramatic results that Health Canada has approved to be safe and effective with NPN registration.
The Rhema Group, a leading nutraceutical formulator and manufacturer to global markets, has partnered with Biologic Pharmamedical Research, a private biomedical research organization, to bring to market patent-protected formulations with BDMC levels elevated to 30% under the trade name Curcumin BDM30™. Both companies are working together to use Cavaleri’s patented research to develop new evidence-based curcumin-drug and supplement designs for the functional food and nutraceutical industry. This inflection is expected to change how curcumin is prescribed in the future to help improve lives.